The Therapy Center LLP is pleased to announce the opening of:

TMS of Westchester.

TMS of Westchester employs NeuroStar TMS for the treatment of clinical depression.

NeuroStar TMS is a safe, FDA cleared office based treatment with the goal of FULL REMISSION.

The NeuroStar TMS Therapy System developed by Neuronetics, offered at TMS of Westchester, is the first and only non-systemic and non-invasive TMS system cleared by the U.S. Food and Drug Administration (FDA) for the treatment of patients with major depressions who have not benefited from prior antidepressant treatment. This non-invasive treatment for depression uses a highly focused, pulsed magnetic field to stimulate function in targeted brain regions. It is made available to patients by prescription only and delivered under the supervision of a psychiatrist.

Neurostar TMS Therapy is non-invasive, meaning that it does not involve surgery. It does not require any anesthesia or sedation, and the patient remains awake and alert during the treatment. TMS Therapy is also non-systemic, meaning that unlike medication, it is not taken by mouth and does not circulate in the blood stream throughout the body. Therefore the commonly reported side effects associated with anti-depressant medications are not experienced by TMS patients.

Antidepressant medication commonly reported side effects include:

• Weight gain
• Dry mouth
• Nausea
• Fatigue
• Drowsiness
• Headache / Migraine
• Insomnia
• Decreased libido
• Impotence
• Anxiety
• Tremor

TMS Therapy commonly reported side effects include:

• Mild to moderate scalp pain which dissipates after the first few treatments

Safe

TMS therapy has been safely administered with over 20 years of research in the treatment of depression. TMS of Westchester uses the NeuroStar TMS therapy system, which is the ONLY TMS device that is FDA cleared and proven safe and effective for the treatment of depression. TMS therapy should not be used on patients with implanted metallic devices or non-removable metallic objects in or around the head.

• In an open-label clinical trial, most like real world clinical practices, 1 out of 2 patients treated with NeuroStar TMS experienced significant improvement in depression symptoms.

• 1 out of 3 experienced complete symptom relief at the end of 6 weeks